Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

Research misconduct ...can delay meaningful and reliable discoveries

Express Pharma

|

October 2025

Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions

- By Viveka Roychowdhury

Research misconduct ...can delay meaningful and reliable discoveries

In terms of peer review fraud, research misconduct, how large is the problem, globally and specifically for pharma/life science research papers being published out of India?

In recent years, we have seen increased reporting in scholarly and traditional news on instances of suspected research misconduct and publication integrity violations. This has ranged from investigations into individual authors or researcher groups to large-scale retraction of many thousands of articles. The observed increase in the number of articles being retracted can be attributed, in part, to improvements in detection systems by publishers; however, it may also reflect a change in the rate of research or publication misconduct.

There are no completely accurate rates of research misconduct or peer review fraud available, in part because of the existence of as yet undiscovered misconduct and the high professional cost of admitting to misconduct. Some attempts to quantify this exist, for example, a 2016 study found that just under 4 per cent of screened published papers contained problematic images [1].

Another study looking at nucleotide sequences found that 713 out of >3400 screened articles contained incorrectly described nucleotide sequences [2]. Even less certain is the prevalence of misconduct in unpublished works. An analysis on paper mills from the Committee on Publication Ethics (COPE) and the STM Association [3] found that publishers reported that between 2-46 per cent of the submissions to a journal can be suspected of having paper mill involvement.

MÁS HISTORIAS DE Express Pharma

Express Pharma

Express Pharma

NEEDLES, PENS AND PRESSURE THE GLP-1 CHALLENGE

As GLP-1 therapies transform diabetes and obesity care, demand for prefilled pens and injectors is soaring. Pharma-device collaborations, analytical innovation, and sustainable design will be key to tackle the growing device bottleneck

time to read

7 mins

November 2025

Express Pharma

Express Pharma

Unified standards and smarter design are key to unlocking next-generation HVAC performance

Current HVAC design relies on a diverse, and sometimes confusing, array of guidelines issued by regulatory bodies such as WHO, EU GMP, ISO 14644, ISPE Baseline, and ASHRAE/ISHRAE.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Kyasanur Forest Disease - How far is a regulatory approved vaccine?

Dr Priyabrata Pattnaik, Former Deputy MD, Indian Immunologicals, informs about the Kyasanur Forest Disease (KFD), a zoonotic viral hemorrhagic fever endemic to parts of India, particularly along the Western Ghats and discusses the current status of developing a regulatory-approved KFD vaccine in India

time to read

3 mins

November 2025

Express Pharma

Express Pharma

India's biopharma industry charts the road from biosimilars to innovation

Express Pharma hosted the maiden Biopharma Leadership Conclave 2025 and brought together industry leaders to discuss how India can move from being the world's leading producer of generics and biosimilars to becoming a hub for innovative, affordable, and high-quality biologics and advanced therapies

time to read

4 mins

November 2025

Express Pharma

Express Pharma

Digital technologies are quietly transforming HVAC into an intelligent compliance partner

Over the last decade, HVAC standards in pharmaceutical manufacturing have undergone a quiet revolution.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Direct-to-Retail will increasingly complement traditional pharma distribution

Aqualab has crossed Rs 100 crore in just three years, what have been the key drivers behind this growth, and how does the brand plan to achieve the Rs 250 crore target by FY25-26?Aqualab's journey to Rs 100 crore within three years reflects the strength of a simple yet powerful principle, accessibility through proximity. Our growth has been anchored in three areas: a high-velocity retail network that prioritises last-mile availability, a well-diversified therapeutic portfolio spanning acute and chronic segments, and a strong focus on brand trust built through consistent product quality.

time to read

3 mins

November 2025

Express Pharma

Express Pharma

Guaranteeing continuity of medicine supply through AI innovation

Hari Kiran Chereddi highlights how AI is transforming pharma supply chains to ensure uninterrupted medicine availability

time to read

2 mins

November 2025

Express Pharma

PROSOLV® 730: Directly compressible carrier for lipophilic ingredients

Nearly 90 % of molecules in the discovery pipeline and 40 % of drugs with market approval are poorly water soluble. Poor aqueous solubility can lead to low bioavailability resulting in insufficient plasma levels. Oil-based preparations of these APIs, as well as oily APIs in general, present challenges in terms of solid dosage form manufacturing. PROSOLV® 730 was designed to provide a solution to the formulation of BCS class II and IV APIs. It enables the formulation of lipidic APIs or API-loaded lipid systems by facilitating the adsorption of oil, creating a free-flowing, compactible system that can be further formulated. PROSOLV® 730 is a co-processed, high-functionality excipient comprising MCC SILICA COPOVIDONE

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Ensuring Clean Room Integrity with Prime Clean Reset High-Speed Doors: Minimizing Air Permeability and Leakages

High-speed doors for clean rooms are specialized industrial doors essential for maintaining controlled environments. These doors are engineered to be airtight, creating a reliable barrier between different areas of a facility. Their design ensures durability and minimal maintenance, reducing the frequency of repairs and replacements.

time to read

2 mins

November 2025

Express Pharma

Express Pharma

Reimagining cold chain: How IoT secures every pharma mile

Swarup Bose, Co-founder and CEO, Celcius Logistics points out that as the demand for temperature-sensitive medicines surges, maintaining an unbroken cold chain has never been more critical. IoT is emerging as the game-changer that ensures every vial and vaccine arrives potent, safe, and on time

time to read

3 mins

November 2025

Listen

Translate

Share

-
+

Change font size